GlassScriptPhysician profile
Gina M Mele
NPI 1467772780
$4,860.94
in general payments reported to CMS, 2019-2025
32 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,200 · 2022: $1,645 · 2023: $1,077 · 2024: $543 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $690.83 | 2021-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $519.44 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $472.41 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $427.24 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $340.11 | 2022-2025 | |
| Lilly USA, LLC | $324.35 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $285.36 | 2021-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.41 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $195.93 | 2021-2025 | |
| Daiichi Sankyo INC. | $167.91 | 2021-2024 | Injectafer |
| Idorsia Pharmaceuticals US INC | $111.40 | 2022-2023 | Quviviq |
| Corcept Therapeutics | $109.17 | 2022-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $106.32 | 2021-2022 | |
| Abbvie INC. | $104.04 | 2021-2025 | |
| Exact Sciences Corporation | $94.80 | 2023-2024 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.46 | 2021-2023 | |
| Endo Pharmaceuticals INC. | $75.43 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $70.40 | 2021-2023 | |
| Mannkind Corporation | $54.21 | 2021-2022 | |
| Medtronic, INC. | $46.72 | 2022 | |
| Merck Sharp & Dohme LLC | $46.69 | 2022-2025 | Gardasil 9, Capvaxive |
| Dexcom, INC. | $45.04 | 2021-2023 | Dexcom G6 Transmitter |
| Ars Pharmaceuticals Operations, INC. | $42.64 | 2025 | Neffy |
| Biohaven Pharmaceuticals, INC. | $31.62 | 2021 | |
| Clarus Therapeutics INC. | $26.16 | 2021 | |
| Esperion Therapeutics, INC. | $25.05 | 2021 | |
| Amarin Pharma, INC. | $19.09 | 2022 | |
| Irhythm Technologies, INC. | $18.99 | 2022 | |
| Hikma Pharmaceuticals USA | $17.92 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Mele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.